Fresenius Kabi Receives Two Major Awards for Supply and Service Excellence from Vizient®
2025 Pharmaceutical Supply Assurance Supplier of the Year for efforts “to strengthen provider’s delivery of better, more affordable care”
National Account Leadership Award to Fresenius Kabi’s Andy Fox for working “diligently and strategically to collaborate with Vizient”
LAKE ZURICH, Ill., Sept. 25, 2025 – Fresenius Kabi, part of the global healthcare company Fresenius, announced today it has received two Service Excellence awards from Vizient®, the nation’s largest provider-driven healthcare performance improvement company.
Customer recognition like this is a testament to the passion and commitment of Fresenius team members across the country and the world, but especially in the company’s U.S. manufacturing and distribution centers, who work 24/7 to assure a strong pharmaceutical supply chain for America. To learn more about Fresenius in America, visit www.moreinamerica.com
“These awards from Vizient are an important acknowledgment of the company’s commitment to long-term, sustainable drug supply,” said Arun Verma, president, Fresenius Kabi USA and a member of the Executive Leadership Team at Fresenius Kabi AG. “The Vizient Supply Assurance award is especially gratifying as it recognizes our efforts to assure continuity of supply for essential medicines and technologies coupled with transparent and timely communication. And while work like this is always a team effort, I want to thank Andy Fox for leading all aspects of our relationship with Vizient. Andy is an experienced leader who embodies the Fresenius Principles every day.”
About Fresenius Kabi
As a global healthcare company, Fresenius Kabi is Committed to Life. The company’s products, technologies, and services are used for the therapy and care of critically and chronically ill patients. With more than 41,000 employees and present in over 130 countries, Fresenius Kabi’s expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies.
In Biopharma, Fresenius Kabi offers cutting-edge biosimilars for autoimmune diseases and oncology. With leading market positions in Clinical Nutrition, a broad portfolio of enteral and parenteral products makes a distinct difference in patients’ nutritional status. In MedTech, the company provides vital infusion pumps, cell and gene therapy devices, disposables, and more. Fresenius Kabi is the global leader in supplying blood collection bags and devices, supporting blood banks and healthcare facilities worldwide. The company’s I.V. Generics and Fluids for infusion therapy help save millions of lives every year, in emergency medicine, surgery, oncology, and intensive care.
Fresenius Kabi takes a holistic approach to healthcare and uniquely combines experience, expertise, innovation, and dedication – making a difference in the lives of 450 million patients annually. With the #FutureFresenius strategy, the company is developing, producing, and selling new products and technologies and aspires to expand its position as a leading global provider of therapies, improve patient care, generate sustainable value for stakeholders – shaping the future of healthcare.
Fresenius Kabi is an operating company of the Fresenius Group, founded in 1912, along with Helios and Quirónsalud. As ONE team, the companies in the Fresenius Group are committed to providing lifesaving and life-changing healthcare solutions on a global scale. For more information, please visit www.fresenius-kabi.com.
###